SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Exagen Inc. – ‘S-1/A’ on 9/9/19 – ‘EX-23.1’

On:  Monday, 9/9/19, at 6:08am ET   ·   Accession #:  1193125-19-240403   ·   File #:  333-233446

Previous ‘S-1’:  ‘S-1’ on 8/23/19   ·   Latest ‘S-1’:  This Filing   ·   26 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/09/19  Exagen Inc.                       S-1/A                 12:4.2M                                   Donnelley … Solutions/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Pre-Effective Amendment to Registration Statement   HTML   1.59M 
                (General Form)                                                   
 2: EX-3.1      Articles of Incorporation/Organization or By-Laws   HTML    137K 
 3: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     15K 
 4: EX-5.1      Opinion of Counsel re: Legality                     HTML     12K 
 5: EX-10.3     Material Contract                                   HTML     82K 
 8: EX-10.34    Material Contract                                   HTML     25K 
 9: EX-10.36    Material Contract                                   HTML     21K 
10: EX-10.37    Material Contract                                   HTML     19K 
11: EX-10.38    Material Contract                                   HTML     14K 
 6: EX-10.4     Material Contract                                   HTML     27K 
 7: EX-10.5     Material Contract                                   HTML     62K 
12: EX-23.1     Consent of Experts or Counsel                       HTML      6K 


‘EX-23.1’   —   Consent of Experts or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-23.1  

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

Exagen Inc.

San Diego, California

We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated May 31, 2019, except for Note 16 which is as of August 23, 2019 and the “Reverse Stock Split” paragraph of Note 17 which is as of September 9, 2019, relating to the financial statements of Exagen Inc., which are contained in that Prospectus.

We also consent to the reference to us under the caption “Experts” in the Prospectus.

/s/ BDO USA, LLP

San Diego, California

September 9, 2019


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1/A’ Filing    Date    Other Filings
Filed on:9/9/19
8/23/19DRS,  DRS/A,  S-1
5/31/19
 List all Filings 


26 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/13/24  Exagen Inc.                       S-8         5/13/24    4:130K
 5/13/24  Exagen Inc.                       10-Q        3/31/24   58:4.7M
 3/18/24  Exagen Inc.                       10-K       12/31/23   76:8.9M
11/27/23  Exagen Inc.                       S-3/A                  3:611K
11/17/23  Exagen Inc.                       S-3                    4:683K                                   Workiva Inc Wde… FA01/FA
11/13/23  Exagen Inc.                       10-Q        9/30/23   59:169M
 8/07/23  Exagen Inc.                       10-Q        6/30/23   55:4.9M
 7/24/23  Exagen Inc.                       8-K:5,8,9   7/24/23   11:172K
 5/18/23  Exagen Inc.                       S-8         5/18/23    4:132K
 5/15/23  Exagen Inc.                       10-Q        3/31/23   57:4.9M
 3/20/23  Exagen Inc.                       10-K       12/31/22   76:9.1M
11/21/22  Exagen Inc.                       10-Q        9/30/22   71:7.3M
11/21/22  Exagen Inc.                       10-Q/A      6/30/22   71:7.2M
 8/04/22  Exagen Inc.                       10-Q        6/30/22   65:6.5M
 5/11/22  Exagen Inc.                       S-8         5/11/22    4:128K
 5/11/22  Exagen Inc.                       10-Q        3/31/22   66:6.1M
 3/22/22  Exagen Inc.                       10-K       12/31/21   73:8.6M                                   Workiva Inc Wde… FA01/FA
11/10/21  Exagen Inc.                       10-Q        9/30/21   67:6.8M
 8/09/21  Exagen Inc.                       10-Q        6/30/21   61:5.8M
 7/30/21  Exagen Inc.                       8-K:5,8,9   7/29/21    2:79K
 5/11/21  Exagen Inc.                       S-8         5/11/21    3:135K
 5/11/21  Exagen Inc.                       10-Q        3/31/21   59:5M
 4/01/21  Exagen Inc.                       10-K/A     12/31/20   14:498K
 3/16/21  Exagen Inc.                       10-K       12/31/20   78:8.7M
11/10/20  Exagen Inc.                       S-3                    5:1.1M
11/10/20  Exagen Inc.                       10-Q        9/30/20   62:5.7M
Top
Filing Submission 0001193125-19-240403   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 3:58:17.3am ET